214 related articles for article (PubMed ID: 30686493)
1. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z
Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
Ademi Z; Zomer E; Tonkin A; Liew D
Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
Kumar R; Tonkin A; Liew D; Zomer E
Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
[TBL] [Abstract][Full Text] [Related]
5. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
[TBL] [Abstract][Full Text] [Related]
6. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
[TBL] [Abstract][Full Text] [Related]
10. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
[TBL] [Abstract][Full Text] [Related]
12. Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis.
Perera K; Kam N; Ademi Z; Liew D; Zomer E
J Clin Lipidol; 2020; 14(6):772-783. PubMed ID: 32994152
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
Gao L; Moodie M; Li SC
Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
[TBL] [Abstract][Full Text] [Related]
18. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
Kodera S; Morita H; Kiyosue A; Ando J; Komuro I
Circ J; 2018 Mar; 82(4):1076-1082. PubMed ID: 29367520
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]